Find and Pitch Jounalists, Get Your Story Covered

Tags: Alzheimer's disease | Alzheimer’s | biotech | biotechnology | Cancer | drug development | Drug prices | drug pricing | finance | Pharmaceuticals | research | Vaccines biotech pharma Research & Development research-development

	Profile	Recent Articles on Subject
1	Ioanna Lykiardopoulou Next Web Prof of Statistical Science. Works at UCL. London, UK statisticsBayesian modelingeducation	The technologies set to drive medtech innovation in 2024 - 5 months ago
2	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	BioMarin appeases an activist - 5 months ago STAT+: 3 trends to watch in biotech in 2024 - 5 months ago Tome Biosciences goes public today in another biotech megaround - 5 months ago Carmot’s chance of beating the odds in the biotech market just ended - 5 months ago STAT+: With biotech in a slump, the industry’s job market is upside down - 6 months ago The return of biotech’s “bump factor” amid an economic downturn - 6 months ago Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots - 6 months ago Cell and gene therapies could be a safer bet than other drugs - 7 months ago STAT+: What ever happened to biotech’s big comeback? - 8 months ago
3	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech updates you need to read today - 5 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 5 months ago The biotech news you missed from the weekend - 5 months ago Novartis is building a new radioligand plant in China - 6 months ago Johnson & Johnson bets heavy on AI-driven drug discovery - 6 months ago A new algorithm unveils CRISPR ‘treasure trove’ - 6 months ago These are the need-to-know biotech stories from this weekend - 6 months ago XBI biotech index rises, giving investors a shred of hope - 6 months ago Shrinking Covid vaccine sales has Moderna course-correcting - 7 months ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - 7 months ago
4	Michael Gibney Pharma Voice	This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain - 5 months ago Real Chemistry’s CEO on biopharma’s outlook in 2024 - 5 months ago A biotech tackles drug discovery with transcription factor know-how - 6 months ago
5	George Budwell Motley Fool Healthcare and science writer. Houston, TX healthcaresciencewriting	1 Biotech Stock That Could Be the Next Amgen - 5 months ago
6	Ben Fidler Pharma Voice	CRISPR eyes autoimmune disease in revamp of cell therapy plans - 5 months ago
7	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Pfizer plans to depart BIO - 5 months ago
8	Emily Hutto MedPage Today Video Producer, MedPageToday. New York City video productionpodcasting	Gaming the Patent System Can Keep Biosimilars Off the Market for Decades - 6 months ago
9	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 6 months ago
10	<em>The Scientist</em>’s Creative Services Team The Scientist	The Art and Science of Synthetic Biology  - 6 months ago

Journalists covering biotech